复方蒲芩片联合莫西沙星治疗社区获得性肺炎的疗效及对血清炎症因子的影响

目的探讨复方蒲芩片联合盐酸莫西沙星氯化钠注射液治疗社区获得性肺炎的临床疗效及对血清炎症因子的影响。方法回顾性分析2020年2月—2021年2月在平煤神马集团总医院治疗的102例社区获得性肺炎患者的临床资料,根据用药的差别分为对照组和治疗组,每组各51例。对照组静脉滴注盐酸莫西沙星氯化钠注射液,0.4 g/次,1次/d;治疗组在对照组基础上口服复方蒲芩片,1 g/次,3次/d。两组均经14 d治疗。观察两组患者临床疗效,比较治疗前后两组患者临床症状改善时间,LCQ、CURB-65和中医症候积分,及血清C反应蛋白(CRP)、白细胞介素-17(IL-17)、基质金属蛋白酶-9(MMP-9)、半乳糖凝聚素-3(Gal-3)和降钙素原(PCT)水平。结果治疗后,治疗组临床有效率明显高于对照组(98.04%vs 82.35%,P0.05)。经治疗,治疗组在临床症状改善时间上均优于对照组(P0.05)。经治疗,两组LCQ评分明显升高,而CURB-65评分和中医症候积分明显下降(P0.05),且治疗组评分明显好于对照组(P0.05)。经治疗,两组血清CRP、IL-17、MMP-9、Gal-3、PCT水平明显下降(P0.05),且治疗组降低更显著(P0.05)。结论复方蒲芩片联合盐酸莫西沙星氯化钠注射液治疗社区获得性肺炎可有效改善患者症状,降低机体炎症反应,提高患者生活质量。

Efficacy of Compound Puqin Tablets combined with moxifloxacin in treatment of community-acquired pneumonia and its effect on serum inflammatory factors

Objective To investigate the clinical efficacy of Compound Puqin Tablets combined with moxifloxacin in treatment of community-acquired pneumonia and its effect on serum inflammatory factors. Methods Retrospective analysis of the clinical data of 102 patients with community-acquired pneumonia in General Hospital of Pingmei Shenma Group from February 2020 to February 2021, and they were divided into control and treatment groups according to different treatments, and each group had 51 cases. Patients in the control group were iv administered with Moxifloxacin Hydrochloride and Sodium Chloride Injection, 0.4 g/time, once daily. Patients in the treatment group were po administered with Compound Puqin Tablets/time, 1 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, the improvement time of clinical symptoms, the scores of LCQ, CURB-65 and TCM syndrome, and the levels of serum CRP, IL-17, MMP-9, Gal-3 and PCT in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (98.04% vs 82.35%, P < 0.05). After treatment, the improvement time of clinical symptoms in the treatment group was better than that in the control group (P < 0.05). After treatment, the LCQ score were significantly increased, while the CURB-65 score and TCM syndrome score were significantly decreased in two groups (P < 0.05), and the scores in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the serum levels of CRP, IL-17, MMP-9, Gal-3 and PCT in two groups were significantly decreased (P < 0.05), especially in the treatment group (P < 0.05). Conclusion Compound Puqin Tablets combined with moxifloxacin in treatment of community-acquired pneumonia can effectively improve the symptoms of patients, reduce the inflammatory reaction, and improve the life treatment.